Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol 2023;170:241-247.
PMID: 36736157